Tetra Bio-Pharma Inc.'s Profile
Pharmaceutical Division – PhytoPain Pharma
- Developing and commercialization of botanical based pharmaceuticals
- Engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases
Recent Highlights
- Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
- For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001
- Acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
- Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content
Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs
- Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
- 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products
WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS
- A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
- Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
- Pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products
PRODUCT PIPELINE
Insomnia Management For Patients With Chronic Pain
- Licensed a hypnotic drug from Mondias Naturals Inc
- Management of Insomnia in patients with chronic pain
- Currently in late stage Phase III clinical testing
PhytoPain To Produce A Combination Product
- Proprietary combination expected to reach Phase I clinical testing in 2017
- Will be ready for market in 2017 due to combination with Mondias Naturals product
Pain Management - Inhalation Cannabis Drug Product
- A prescription drug for management of uncontrolled pain in cancer patients
- Health Canada will provide guidance during Phase I clinical trial
- Commencing December 2016. Anticipating 3-5 year product development
A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.
OPERATIONS OVERVIEW - MMPR
MMPR Division - Collaboration Agreement
- National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.
- MP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions to pursue its research and development objectives and become a world leader in the development and commercialization of Cannabis-based products
- March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
- Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
- Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
- Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller
Management & Directors
-
Ryan Brown
CEORyan has an extensive background in hydroponic equipment manufacturing and distribution throughout North America. As A provider to the industry he worked closely with medicinal cannabis growers in Canada as well as in the United States. over the past five years he has worked in conjunction with medicinal cannabis producers and research facilities around the world focused on the Genetic selection , standardization and breeding of medicinal cannabis Strains to address specific medical symptoms. he has worked closely with doctors and patients improving there access to and knowledge of cannabis therapeutics. Ryan has a unique understanding of both cultivation practices and the needs of patients that will serve as a significant asset to the diversification of grow pros cannabis inc.
-
Norm Boucher,
Security AdvisorNorm’s 30 year career with the RCMP saw him involved in various task force operations in Canada as well as overseas in Spain and the Dominican Republic.
-
Valerie Lasher
Special AdvisorA former manager of the Health Canada MMAR (medical marijuana access regulations) program. She will bring over 30 years of experience and expertise in government regulations and policy management to GrowPros and its partners.
-
Andre Audet
DirectorAndre has held CEO and Director positions for several publicly listed resource companies in Canada including Everton Resources, Majescor Resources and Mazorro Resources.
-
Steve Abboud
Technical AdvisorSteve has been in the hydroponic and medical cannabis business for over 17 years. During this time, he has established an international network of business partners while conducting medical cannabis growing seminars. Steve has developed an acute expertise as a large-scale medical marijuana producer.
-
Charles Campbell
Director – Medical ResearchCharles has worked as a graduate researcher in basic science laboratories for six years. He obtained his B.Sc. in 2009 from the University of Ottawa, where he is currently concluding his Doctoral studies. In addition to a comprehensive knowledge of basic neurobiology, Charles has extensive experience in concisely disseminating complex scientific concepts to groups of varying levels of expertise.
Broker Fact Sheet
-
TBP Broker Fact Sheet
Thu Mar 29, 2019Fact sheet details
Company Links
-
Tue Nov 15 2016, 05:35PMCanada’s medical marijuana space, due to the country’s first mover advantage over many other nations, has attracted international attention. The sector has not disappointed, delivering solid, sometimes spectacular, returns to investors at home and abroad.